Slide 1: Results Presentation for the Full Year Ended 30 June 2021
For personal use only For immediate release 18 August 2021 RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2021 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and C
Slide 2: CSL Limited 2021 Full Year Results
For personal use only CSL Limited 2021 Full Year Results 18 August, 2021 Paul Perreault Joy Linton CEO and Managing Director CFO
Slide 3: Important Notice and Disclaimer
For personal use only IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does no
Slide 4: CEO Overview
For personal use only CEO Overview Paul Perreault CEO & Managing Director
Slide 5: Highlights
Highlights1 Revenue up 10% with net profit after tax up 10% For personal use only CSL Behring Seqirus • HIZENTRA® +15% • Seasonal influenza vaccines +41% • HAEGARDA® +14% • COVID-19 has produced a • Record volume ~130 million headwind for Behring and a • KCENTRA® +7% tailwind for Seqirus doses distr
Slide 6: CSL Behring
CSL Behring Revenue up 6%1 For personal use only Sales Change1 Therapy $m % Region1 Immunoglobulins 4,238 3% - IVIG 2,696 (3%) - SCIG 1,542 15% ROW Albumin 1,071 61% 44% 6% Haemophilia 1,107 (4%) Asia Pac 18% - Recombinants 674 0% US$8.6B - Plasma 433 (9%) North America 5% Specialty 1,770 2% 6% 49%
Slide 7: Immunoglobulins
Immunoglobulins Sales up 3%1 For personal use only • Significant patient needs in core indications • Strong growth in HIZENTRA® +15% driven by: − Increased preference for home treatment – Continued steady uptake for CIDP in US: Market − Only company with SCIG & IVIG treatments for CIDP • Global Ig d
Slide 8: Albumin
Albumin Sales up 61%1 For personal use only China • New distribution model fully operational with sales now normalised: − direct management of 180+ distributors − geographic coverage expanded Market − increased penetration to retail pharmacy and lower tier • Preference for albumin over cities/hospit
Slide 9: Haemophilia
Haemophilia Sales down 4%1 For personal use only Recombinant Coags PD Coags • IDELVION® +2% • HUMATE® +13% − Market leader in Haem B − Growth underpinned by − Compelling clinical profile increased share in vWF in continuing to drive patient US demand & market share • Demand for BERIATE® & Market − C
Slide 10: Specialty Products
Specialty Products Sales up 2%1 For personal use only HAE Hospital Products FY21 Sales $1.8B HAEGARDA® +14% • KCENTRA® +7% Other • Strong global patient growth • RIASTAP® -1% Zemaira − Most patients on therapy • Wound healing -19% Wound since launch Healing • Growth tempered by Haegarda − Demand dri
Slide 11: Plasma Collections
Plasma Collections For personal use only Challenges Initiatives • Plasma collections • Enhanced operating & marketing adversely impacted initiatives to attract lapsed and new by: donors – US stimulus, stay- • Strong adoption of new technology at-home orders, (donor app, kiosks, online) extended 25 n
Slide 12: Plasma Collections: Initiatives driving donor growth
Plasma Collections Initiatives driving donor growth For personal use only DONORS PER WEEK • Annual tax season drop • Pandemic and lockdowns begin Holiday Season • Vaccine momentum • Further initiatives • Stimulus burn-off Initiatives US fiscal launched stimulus JAN FEB MAR APR MAY JUN JULY AUG SEP O
Slide 13: Seqirus
Seqirus Revenue up 30%1 For personal use only Sales Change1 Region1 Therapy $m % QIV 702 28% Seasonal ROW Influenza Adjuvanted 629 60% vaccines 6% TIV 45 49% +41% Asia Pac Other / In-licence 176 (11%) 15% Total Product Sales 1,552 33% US$1.7B North America Pandemic 160 5% 30% 61% 31% Other Income 24
Slide 14: Seqirus Operating Highlights and Looking Forward
Seqirus For personal use only Operating Highlights Looking Forward • Significant growth in seasonal • Next generation self-amplifying influenza vaccines driven by mRNA – Phase 1 expected to ongoing shift to differentiated commence in 2022 products • FLUAD® QIV launch in EU NH • Record volume ~130 mi
Slide 15: R&D Highlights
R&D Highlights For personal use only Immunology Hematology Respiratory • PRIVIGEN® for CIDP • uniQure announced positive data from Phase III trial of EtranaDez • First patient enrolled in launched in Japan CSL787 Nebulised Ig Phase I • Anti-trust clearance received; licence agreement with uniQure st
Slide 16: Financials
For personal use only Financials Joy Linton CFO
Slide 17: Financial Highlights
China GSP • Albumin sales normalised Financial Highlights Net profit after tax COVID For personal use only • Company Response (R&D, manufacturing, cost control measures) +13% $2,375m reported • Reduced social mobility FX$68m impacting therapy demand, $2,307 m plasma collections & HPV @CC1 royalties
Slide 18: Financial Highlights: CSL Group
Financial Highlights CSL Group For personal use only FY20 FY21 FY21 Change 1 Reported Reported at CC % Total Revenue 9,151 10,310 10,026 10%1 Gross Profit 5,226 5,843 5,675 9%1 GP margin 57.1% 56.7% 56.6% EBIT 2,717 3,130 3,025 11%1 EBIT margin 29.7% 30.4% 30.2% NPAT 2,103 2,375 2,307 10%1 Cashflow
Slide 19: Financial Highlights: Segments
Financial Highlights Segments For personal use only CSL Behring Seqirus FY20 FY21 Change FY20 FY21 Change US$ Millions Reported Reported % at CC 1 US$ Millions Reported Reported % at CC 1 Sales 7,661 8,428 7% Sales 1,136 1,552 33% Other Other 193 146 -25% 161 184 9% Revenue Revenue Total Total 7,854
Slide 20: Financial Highlights: Expenses
Modest expense growth over full year Financial Highlights • Uplift in 2H as foreshadowed Reported Expenses For personal use only R&D • Programs paused 1H, now 1 Change @ CC recommenced FY21 $m $m % Research & Sales and Marketing 1,001 47 5% Development • Uplift in commercial launch activities Sales
Slide 21: Inventory: Active management
Inventory Active management For personal use only $M Inventory Key Insights • Inventory as a percentage of revenue relatively steady despite dynamic environment • Higher raw materials component driven by increased plasma cost • Active management of finished goods 20
Slide 22: Key Capital Projects
Key Capital Projects Completion Timeline For personal use only FY22 FY23 FY24 FY25 FY26 FY27 Marburg Base Frac Broadmeadows: Mod 1 & 2 Broadmeadows: Mod 3 Future Base Frac Zemaira Fill/Finish – Thermo Fisher Bulk & Future IG Modules Finishing Broadmeadows Albumin Expansion Lengnau Plasma Centers (Co
Slide 23: CSL Strategy and Values
For personal use only CSL Strategy and Values Strategic Overview Core Patient Focus Innovation Integrity Collaboration Superior Values We deliver on We turn innovative We walk the talk We are stronger Performance our promise to thinking into together We take pride in patients solutions our results C
Slide 24: Outlook for FY22
Outlook for FY221 For personal use only CSL Behring Seqirus • Underlying IG demand • Seqirus’ product differentiation expected to remain strong and COVID-19 expected to drive • IG & albumin sales reliant on strong demand for influenza vaccines FY221 Outlook current plasma collections and cycle times
Slide 25: CSL Contacts
For personal use only CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 3 9389 6798 stephen.mckeon@csl.com.au
Slide 26: Notes
Notes For personal use only (#) Constant currency removes the impact of Summary NPAT exchange rate movements to facilitate Reported net profit after tax $2,375.0m Translation currency effect (a) $ (23.3m) comparability of operational performance for the Transaction currency effect (b) $ (25.4m) Grou